Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.

Published on May 20, 2020in Breast Cancer Research and Treatment3.471
· DOI :10.1007/S10549-020-05674-7
Joyce O'Shaughnessy49
Estimated H-index: 49
(Baylor University Medical Center)
  • References (2)
  • Citations (0)
#1Jill R. DietzH-Index: 13
#1Jill R. Dietz (Case Western Reserve University)H-Index: 5
Last. Paul L. Baron (Yeshiva University)H-Index: 1
view all 19 authors...
The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority l...
14 CitationsSource
#1Julia BeckH-Index: 17
#2Patrick NevenH-Index: 59
Last. Lowell L. HartH-Index: 30
view all 14 authors...
Background: In the MONALEESA (ML) trials, addition of ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) prolonged progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). RIB was generally well tolerated, with adverse events (AEs) managed effectively by dose modifications. Here we present efficacy data for RIB-based regimens of interest for the proposed indication (i.e. with a non-s...
Cited By0